Just saw/posted on this.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
If you want to start a new thread, why don't you call it Stoney's Breakfast Club.
It might gain traction, perhaps migrate some followers from Reddit and WSB's.
Plus that's what we are here anyway. Sort of.
Preparation for our daily podcast.
Last edited:
I woke up praying Granny was still short CVAC. But I fear I may have told her to cover at $97.-?
Priceless & on point!
Please tell me your joking. We put Granny short at $117 you know that. You are breaking my heart I thought we had the call of the century...
CVAC's fail is great news for NVAX!-- May enter today!
Tues)
Novavax price target raised to $272 from $217 at Cantor Fitzgerald 07:00 NVAX Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Novavax to $272 from $217 and keeps an Overweight rating on the shares. Duncan has enhanced conviction for the SARS-CoV-2 vaccine candidate NVX-CoV2373, which had positive topline data from its second Phase 3 study, the U.S./Mexico PREVENT-19 trial, the analyst tells investors in a research note. Duncan believes the Phase 3 data reduce clinical and regulatory risk for a differentiated clinical and logistics profile for '2373 and facilitate EUA submissions expected in 3Q21, potentially with approvals in several countries in 2021. Show Related Items >>
Hey watch the vertical farming sector, big IPO or SPAC I think SPAC coming, two new players bodes well for Agrify I think.
This type of farming uses much less water. Water a HUge problem now.
Agrify Corporation (AGFY)
$10.52+0.93 (+9.70%)
At close: June 16 4:00PM EDT
Tues)
Novavax price target raised to $272 from $217 at Cantor Fitzgerald 07:00 NVAX Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Novavax to $272 from $217 and keeps an Overweight rating on the shares. Duncan has enhanced conviction for the SARS-CoV-2 vaccine candidate NVX-CoV2373, which had positive topline data from its second Phase 3 study, the U.S./Mexico PREVENT-19 trial, the analyst tells investors in a research note. Duncan believes the Phase 3 data reduce clinical and regulatory risk for a differentiated clinical and logistics profile for '2373 and facilitate EUA submissions expected in 3Q21, potentially with approvals in several countries in 2021. Show Related Items >>
Hey watch the vertical farming sector, big IPO or SPAC I think SPAC coming, two new players bodes well for Agrify I think.
This type of farming uses much less water. Water a HUge problem now.
Agrify Corporation (AGFY)
$10.52+0.93 (+9.70%)
At close: June 16 4:00PM EDT
What's up with Squarespace? I think I always thought it was Square. Or Space. Never really occurred to me that there is a different company-
ACCELERATING SECULAR TAILWINDS:Mizuho analyst Dan Dolev initiated coverage of Affirm (AFRM) with a Buy rating and $90 price target. The company should benefit from "accelerating secular tailwinds" in the U.S. buy-now-pay-later market, Dolev told investors in a research note. The analyst sees a "clear path" to sustained 30%-35% long-term annual sales growth and 20%-30% long-term margins.
BUY SQUARESPACE:Mizuho analyst Siti Panigrahi initiated coverage of Squarespace (SQSP) with a Buy rating and $80 price target. Squarespace offers a "robust" software-as-a-service platform to build websites and is "differentiated through aesthetic appeal, ease of use, and features to garner market share in the digital goods and services marketplace," Panigrahi told investors in a research note. The analyst sees Squarespace as a "compelling investment with a valuation that does not yet reflect its promising fundamentals."
ACCELERATING SECULAR TAILWINDS:Mizuho analyst Dan Dolev initiated coverage of Affirm (AFRM) with a Buy rating and $90 price target. The company should benefit from "accelerating secular tailwinds" in the U.S. buy-now-pay-later market, Dolev told investors in a research note. The analyst sees a "clear path" to sustained 30%-35% long-term annual sales growth and 20%-30% long-term margins.
BUY SQUARESPACE:Mizuho analyst Siti Panigrahi initiated coverage of Squarespace (SQSP) with a Buy rating and $80 price target. Squarespace offers a "robust" software-as-a-service platform to build websites and is "differentiated through aesthetic appeal, ease of use, and features to garner market share in the digital goods and services marketplace," Panigrahi told investors in a research note. The analyst sees Squarespace as a "compelling investment with a valuation that does not yet reflect its promising fundamentals."
I think this is good...
DavidsTea obtains recognition order from US Bankruptcy Court 09:23 DTEA DAVIDsTEA announce that…
DavidsTea obtains recognition order from US Bankruptcy Court 09:23 DTEA DAVIDsTEA announce that…